MVASI® is a vascular endothelial growth factor inhibitor indicated for the treatment of: MVASI®, in combination with intravenous fluorouracil-based chemotherapy, is indicated for the first- or second-line treatment of patients with metastatic colorectal cancer (mCRC).... Read More
Amgen Assist 360™ is a single place for patients, caregivers, and healthcare professionals to go to find the support, tools, and resources most important to them.
CALL 1-888-4ASSIST
(1-888-427-7478)
Monday to Friday
9:00 am to 8:00 pm ET
or visit www.AmgenAssist.com/copay.
Amgen Assist 360™ is a single place for patients, caregivers, and healthcare professionals to go to find the support, tools, and resources most important to them.
BENEFIT VERIFICATION
Submit, store, and retrieve benefit verifications for all patients currently on Amgen medications electronically with ease from our secure Amgen Assist 360™ Provider Portal.
REIMBURSEMENT COUNSELORS
Call an Amgen Reimbursement Counselor directly for your benefit verification needs.
FIELD REIMBURSEMENT SPECIALISTS
Schedule a remote or live appointment with a Field Reimbursement Specialist who can assist with:
AMGEN NURSE NAVIGATORS ARE AVAILABLE TO SUPPORT YOUR PATIENTS*
Patients are connected with a single point of contact who can help them find resources that are most important to them.* Amgen Nurse Navigators are there to support, not replace, your treatment plan and are trained to assist a patient with financial coverage and referrals to resources that may help their emotional wellness throughout their treatment journey.†
For eligible‡ commercially insured patients, the Amgen FIRST STEP™ Co-pay Program can help.
If your patients have questions about their Amgen medication, we can help them get the answers they need.
Patients can learn about independent nonprofit organizations that may provide community resources, one-on-one counseling services, and local support groups.
To enroll your patients in the Amgen FIRST STEP™ Co-pay Program, please call 1-888-4ASSIST (1-888-427-7478) or visit www.AmgenAssist.com/copay.
The Amgen FIRST STEP™ Co-pay Program is here to help eligible commercially insured patients pay for their out-of-pocket prescription costs.
AMGEN HAS AN UNWAVERING COMMITMENT TO DELIVER OUR PRODUCTS, INCLUDING MVASI®, TO EVERY PATIENT, EVERY TIME
Order resources to help you administer MVASI® and guide conversations with patients. Or, learn more about prescribing MVASI® for your patients.
*Resources include referrals to independent nonprofit patient assistance programs. Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofit’s criteria. Amgen has no control over these programs and provides referrals as a courtesy only.
†Amgen Nurse Navigators are only available to patients that are prescribed certain products. Nurse Navigators are there to support, not replace, your treatment plan and do not provide medical advice or case management services. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.
‡Terms, conditions, and program maximums apply. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program. Not valid where prohibited by law.
§$25 out-of-pocket cost for each dose of PROLIA® (denosumab) through Amgen FIRST STEP™.
**Terms, conditions, and program maximums apply. Other restrictions may apply. See the Amgen FIRST STEP™ Co-pay Program Terms and Conditions for details. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program. Not valid where prohibited by law.
Serious adverse reactions (Warnings and Precautions)
Pregnancy warning
Most common adverse reactions
Indication-specific adverse reactions
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch.
You may also report side effects to Amgen at 1-800-772-6436.
Please see full Prescribing Information for additional Important Safety Information.
INDICATIONS
MVASI® is a vascular endothelial growth factor inhibitor indicated for the treatment of:
MVASI®, in combination with intravenous fluorouracil-based chemotherapy, is indicated for the first- or second-line treatment of patients with metastatic colorectal cancer (mCRC).
MVASI®, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, is indicated for the second-line treatment of patients with mCRC who have progressed on a first-line bevacizumab product-containing regimen.
Limitations of Use: MVASI® is not indicated for adjuvant treatment of colon cancer.
MVASI®, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC).
MVASI® is indicated for the treatment of recurrent glioblastoma (GBM) in adults.
MVASI®, in combination with interferon-alfa, is indicated for the treatment of metastatic renal cell carcinoma (mRCC).
MVASI®, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer (CC).
MVASI®, in combination with carboplatin and paclitaxel, followed by MVASI® as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection (OC).
MVASI®, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens (OC).
MVASI®, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by MVASI® as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (OC).
MVASI® is a trademark of Amgen, Inc.
Avastin® (bevacizumab) is a registered trademark of Genentech USA, Inc.
MVASI® Important Safety Information
Serious adverse reactions (Warnings and Precautions)